{"id":1020080,"date":"2026-11-11T13:42:12","date_gmt":"2026-11-11T18:42:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/"},"modified":"2026-11-11T13:42:12","modified_gmt":"2026-11-11T18:42:12","slug":"kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/","title":{"rendered":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nKyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX<\/p>\n<p>NEW ORLEANS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nFormer Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-kytx%2F%3Fprs%3Dbw&amp;esheet=54639795&amp;newsitemid=20261111024114&amp;lan=en-US&amp;anchor=Kyverna+Therapeutics&amp;index=1&amp;md5=ba723eab374d16bd491f81c3c4874f56\">Kyverna Therapeutics<\/a>, Inc. (\u201cKyverna\u201d or the \u201cCompany\u201d) (NasdaqGS: KYTX).<\/p>\n<p>\nAccording to a securities lawsuit filed against the Company, the registration statement and prospectus Kyverna used to conduct its initial public offering on February 8, 2024 (the \u201cIPO\u201d) misstated and\/or omitted material facts about the results of the Company\u2019s ongoing clinical evaluation of KYV-101, its lead product candidate. Specifically, the lawsuit alleges that Kyverna touted patient \u201cimprovement\u201d in certain indicators while failing to disclose adverse data from one of its clinical trials, even though that data was known to the Company at the time of the IPO. As a result, investors allegedly purchased Kyverna shares at artificially inflated prices. When the true details entered the market, the lawsuit claims, investors suffered damages.<\/p>\n<p>\nKSF\u2019s investigation is focusing on whether Kyverna\u2019s officers and\/or directors of breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.<\/p>\n<p>\nIf you have information that would assist KSF in its investigation, or have been a long-term holder of Kyverna\u2019s shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn (<a rel=\"nofollow\" href=\"mailto:lewis.kahn@ksfcounsel.com\">lewis.kahn@ksfcounsel.com<\/a>), or visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-kytx%2F%3Fprs%3Dbw&amp;esheet=54639795&amp;newsitemid=20261111024114&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-kytx%2F&amp;index=2&amp;md5=ebeafa1a764a09b57c6181af315826e2\">https:\/\/www.ksfcounsel.com\/cases\/nasdaqgs-kytx\/<\/a> to learn more.<\/p>\n<p>\nAbout Kahn Swick &amp; Foti, LLC<\/p>\n<p>\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation\u2019s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors &#8211; in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.<\/p>\n<p>\nTOP 10 Plaintiff Law Firms &#8211; According to ISS Securities Class Action Services<\/p>\n<p>\nTo learn more about KSF, you may visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ksfcounsel.com&amp;esheet=54639795&amp;newsitemid=20261111024114&amp;lan=en-US&amp;anchor=www.ksfcounsel.com&amp;index=3&amp;md5=637e28732f66c1f7aac9bbd44c5b7130\">www.ksfcounsel.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261111024114\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261111024114\/en\/<\/a><\/span><\/p>\n<p>\nKahn Swick &amp; Foti, LLC<br \/>\n<br \/>Lewis Kahn, Managing Partner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lewis.kahn@ksfcounsel.com\">lewis.kahn@ksfcounsel.com<br \/>\n<\/a><br \/>1-833-538-3606<br \/>\n<br \/>1100 Poydras St., Suite 960<br \/>\n<br \/>New Orleans, LA 70163<\/p>\n<p><b>KEYWORDS:<\/b> Louisiana United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261111024114\/en\/2664610\/3\/2025-PR-DER.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211; Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Kyverna Therapeutics, Inc. (\u201cKyverna\u201d or the \u201cCompany\u201d) (NasdaqGS: KYTX). According to a securities lawsuit filed against the Company, the registration statement and prospectus Kyverna used to conduct its initial public offering on February 8, 2024 (the \u201cIPO\u201d) misstated and\/or omitted material facts about the results of the Company\u2019s ongoing clinical evaluation of KYV-101, its lead product candidate. Specifically, the lawsuit alleges that Kyverna touted patient \u201cimprovement\u201d &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1020080","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211; Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Kyverna Therapeutics, Inc. (\u201cKyverna\u201d or the \u201cCompany\u201d) (NasdaqGS: KYTX). According to a securities lawsuit filed against the Company, the registration statement and prospectus Kyverna used to conduct its initial public offering on February 8, 2024 (the \u201cIPO\u201d) misstated and\/or omitted material facts about the results of the Company\u2019s ongoing clinical evaluation of KYV-101, its lead product candidate. Specifically, the lawsuit alleges that Kyverna touted patient \u201cimprovement\u201d &hellip; Continue reading &quot;Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T18:42:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX\",\"datePublished\":\"2026-11-11T18:42:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/\"},\"wordCount\":460,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/\",\"name\":\"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-11T18:42:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/","og_locale":"en_US","og_type":"article","og_title":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Market Newsdesk","og_description":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211; Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d), announces that KSF has commenced an investigation into Kyverna Therapeutics, Inc. (\u201cKyverna\u201d or the \u201cCompany\u201d) (NasdaqGS: KYTX). According to a securities lawsuit filed against the Company, the registration statement and prospectus Kyverna used to conduct its initial public offering on February 8, 2024 (the \u201cIPO\u201d) misstated and\/or omitted material facts about the results of the Company\u2019s ongoing clinical evaluation of KYV-101, its lead product candidate. Specifically, the lawsuit alleges that Kyverna touted patient \u201cimprovement\u201d &hellip; Continue reading \"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-11T18:42:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX","datePublished":"2026-11-11T18:42:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/"},"wordCount":460,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/","name":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-11T18:42:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261111024114r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kyverna-therapeutics-investigation-initiated-kahn-swick-foti-llc-investigates-the-officers-and-directors-of-kyverna-therapeutics-inc-kytx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kyverna Therapeutics Investigation Initiated: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. &#8211; KYTX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1020080"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020080\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1020080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1020080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1020080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}